Spinal muscular atrophy (SMA) is one of the leading genetic diseases of children and infants. SMA is caused by deletions or mutations of Survival Motor Neuron 1 ( SMN1 ) gene. SMN2 , a nearly identical copy of SMN1 , cannot compensate for the loss of SMN1 due to predominant skipping of exon 7. While various regulatory elements that modulate SMN2 exon 7 splicing have been proposed, intronic splicing silencer N1 (ISS-N1) has emerged as the most promising target thus far for antisense oligonucleotide-mediated splicing correction in SMA. Upon procuring exclusive license from the University of Massachussets Medical School in 2010, Ionis Pharmaceuticals (formerly ISIS Pharamaceuticals) began clinical development of Spinraza ™ (synonyms: Nusinersen, IONIS-SMN RX , ISIS-SMN RX ), an antisense drug based on ISS-N1 target. Spinraza ™ showed very promising results at all steps of the clinical development and was approved by US Food and Drug Administration (FDA) on December 23, 2016. Spinraza ™ is the first FDA-approved treatment for SMA and the first antisense drug to restore expression of a fully functional protein via splicing correction. The success of Spinraza ™ underscores the potential of intronic sequences as promising therapeutic targets and sets the stage for further improvement of antisense drugs based on advanced oligonucleotide chemistries and delivery protocols.
Inhalt
- Regular Articles
-
26. Januar 2017
- Regular Articles
- Regular Articles
- Regular Articles
- Regular Articles
-
30. April 2017
- Regular Articles
-
30. April 2017
- Regular Articles
-
11. Mai 2017
- Regular Articles
- Regular Articles
-
31. Mai 2017
- Regular Articles
- Regular Articles
- Regular Articles
-
12. August 2017
- Regular Articles
-
14. September 2017
- Regular Articles
-
12. September 2017
- Regular Articles
-
Open AccessSolitaire stent in the treatment of acute ischemic stroke with large cerebral artery occlusion15. Oktober 2017
- Regular Articles
-
15. Oktober 2017
- Regular Articles
-
28. Oktober 2017
- Regular Articles
-
2. November 2017
- Regular Articles
-
29. Oktober 2017
- Regular Articles
-
28. Oktober 2017
- Regular Articles
-
15. November 2017
- Regular Articles
-
15. November 2017
- Regular Articles
-
Open AccessOne-shot synesthesia25. November 2017
- Regular Articles
-
30. November 2017
- Regular Articles
-
19. Dezember 2017
- Regular Articles
- Regular Articles
-
29. Dezember 2017
- Regular Articles
-
29. Dezember 2017
- Regular Articles
-
29. Dezember 2017